減毒活病毒疫苗市場報告：2030 年趨勢、預測與競爭分析

減毒活病毒疫苗的趨勢與預測

到 2030 年，全球減毒活病毒疫苗市場預計將達到 98 億美元，2024 年至 2030 年複合年成長率為 9.5%。該市場的主要促進因素包括對更有效疫苗的需求不斷成長、人們對疫苗接種益處的認知不斷提高以及政府為加強疫苗接種計劃而採取的支持措施。全球減毒活病毒疫苗市場前景廣闊，醫院、診所、診斷中心和研究機構市場充滿機會。

Lucintel 預測，由於病毒感染在有效預防病毒性行為感染的廣泛應用，預計在預測期內性行為感染將出現高速成長。

在這個市場中，預計醫院將在預測期內實現最高成長。

常問問題

Q.1減毒活病毒疫苗的市場規模有多大？

A1. 到 2030 年，全球減毒活病毒疫苗市場預計將達到 98 億美元。

Q.2減毒活病毒疫苗市場的成長預測是多少？

A2. 2024年至2030年，全球減毒活病毒疫苗市場預計將以9.5%的複合年成長率成長。

Q.3 影響減毒活病毒疫苗市場成長的關鍵促進因素有哪些？

A3. 該市場的主要驅動力是對更有效疫苗的需求不斷成長、人們對疫苗接種益處的認知不斷提高以及政府支持加強疫苗接種計劃的舉措。

Q4.市場的主要細分市場是：

A4.減毒活病毒疫苗市場前景廣闊，醫院、診所、診斷中心和研究機構市場充滿機會。

Q5.市場的主要企業是：

A5. 主要減毒活病毒疫苗企業如下：

• GlaxoSmithKline
• Merck & Co
• Medimmune
• Sanofi
• Serum Institute India
• Emergent Biosolutions
• CSL

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預測，由於病毒在有效預防性行為感染的重要用途，預計在預測期內病毒將呈現高速成長。

Q7.未來五年預計哪些地區的市場成長最大？

A7. 由於其發達的醫療基礎設施和政府疫苗宣傳活動，預計北美在預測期內將出現最高的成長。

Q8. 可以客製化報告嗎？

A8. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章全球減毒活病毒疫苗市場：市場動態

• 簡介、背景、分類
• 供應鏈
• 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

• 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
• 全球減毒活病毒疫苗市場趨勢（2018-2023）與預測（2024-2030）
• 按類型分類的全球減毒活病毒疫苗市場
  • 細菌
  • 病毒性的
• 按最終用途分類的全球減毒活病毒疫苗市場
  • 醫院
  • 診所
  • 診斷中心
  • 研究所
  • 其他

第4章 2018-2030年區域市場趨勢及預測分析

• 全球減毒活病毒疫苗市場區域分佈
• 北美減毒活病毒疫苗市場
• 歐洲減毒活病毒疫苗市場
• 亞太地區減毒活病毒疫苗市場
• 其他地區減毒活病毒疫苗市場

第5章 競爭分析

• 產品系列分析
• 營運整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 全球減毒活病毒疫苗市場的成長機會（按類型）
  • 全球減毒活病毒疫苗最終用途市場成長機會
  • 全球減毒活病毒疫苗市場成長機會（按地區）
• 全球減毒活病毒疫苗市場新趨勢
• 戰略分析
  • 新產品開發
  • 全球減毒活病毒疫苗市場產能擴張
  • 全球減毒活病毒疫苗市場的合併、收購與合資企業
  • 認證和許可

第7章主要企業概況

• GlaxoSmithKline
• Merck & Co
  • MedImmune
• Sanofi
• Serum Institute India
• Emergent Biosolutions
• CSL

Live Attenuated Vaccine Trends and Forecast

The future of the global live attenuated vaccine market looks promising with opportunities in the hospital, clinic, diagnostics center, and research institute markets. The global live attenuated vaccine market is expected to reach an estimated $9.8 billion by 2030 with a CAGR of 9.5% from 2024 to 2030. The major drivers for this market are cumulating need for more effective vaccines, expanding awareness of the benefits of vaccination, and supportive government initiatives to promote vaccination programs.

Lucintel forecasts that viral is expected to witness higher growth over the forecast period due to its significant usage for the effective prevention of viral infections.

Within this market, hospital is expected to witness highest growth over the forecast period.

Emerging Trends in the Live Attenuated Vaccine Market

The live attenuated vaccine market is in flux, with a number of emerging trends pushing experimentation and market expansion. Included among these are technological advances being made with vaccines and the global fight against infectious diseases.

• Next-Generation Vaccine Development: An increasing emphasis is being placed on the production of newer live attenuated vaccines that are safer, more efficient and can target several pathogens simultaneously. Consequently, such vaccines are aimed at amplifying immune reactions while minimizing reactions thus making them applicable to various demographics.
• Alternative Delivery Methods: New ways of administering live attenuated vaccines like intranasal sprays and oral formulations have come up. Instead of traditional injections, these provide an easier means of administering the drug especially to pediatric as well as geriatric patients and they also offer better vaccine availability in countries lacking robust healthcare systems.
• Personalized Vaccination: The market has witnessed a significant shift towards personalized vaccines that are based on individual genetic traits. These vaccines aim to fine-tune immune system responses using genetic factors which could potentially increase efficacy while reducing adverse effects thus leading to more personalized vaccination strategies.
• Global Distribution and Accessibility: Ensuring that the global distribution of live attenuated vaccines is done equitably is a growing issue of concern. Activities are being undertaken to increase vaccine distribution networks notably in the low- and middle-income nations. The partnerships between governments, NGOs, and pharmaceutical companies are key to global vaccination objectives.
• Regulatory Innovation: Regulatory authorities are increasingly adopting more flexible and fast approval procedures for live attenuated vaccines. This move has been occasioned by the need to respond rapidly to emerging public health threats, which in turn paves way for new vaccines' rapid entry into market.

These trends reshape live attenuated vaccine marketplace stimulating innovation, enhancing accessibility, and enabling the adaptation of immunizations to better address global health requirements.

Recent Developments in the Live Attenuated Vaccine Market

This market has been undergoing significant progress due to advancements in research, production, and global health initiatives. These advances are essential for improving vaccine effectiveness, reachability, and supply.

• mRNA-Enhanced Live Attenuated Vaccines: Incorporating mRNA technology into live attenuated vaccines is a landmark development. It is used for enhancing the immune response especially in influenza and COVID-19 vaccines resulting in improved efficacy and wider protection.
• Inhalable Vaccines: The development of inhalable live attenuated vaccines is a major milestone. This way provides an alternative mode of administration to injections that makes it easier and more acceptable for vaccination especially among pediatrics and elderly people.
• Vaccine Production Expansion: A housing vaccine production facilities' expansion particularly at India and China represents one major step forward. These expansions are aimed at meeting the increasing global demand for live attenuated vaccines so as they are available in developed as well as developing countries.
• Global Vaccine Distribution Initiatives: New partnerships and initiatives focused on global vaccine distribution are emerging most especially in low income middle-income nations. Such efforts will ensure fairness when accessing live attenuated vaccines while bridging global health disparities.
• Fast-Tracking of Regulations: Regulatory authorities are putting in place fast-tracked procedures for attenuated live vaccines, particularly during pandemics. Such a development speeds up the production of new vaccines and as such helps in dealing with emerging health issues without delays.

These changes are at the forefront of the Live attenuated vaccine industry to make vaccines more efficient, reach many people and be available all over the world to solve worldwide health problems.

Strategic Growth Opportunities for Live Attenuated Vaccine Market

The live attenuated vaccine market is having a number of strategic growth areas in different applications, which are primarily driven by technology changes and global demand for effective vaccines.

• Pediatric Immunization Programs: There is an expanding pediatric immunization programs that have significantly increased potential. Young children-focused live attenuated vaccines expand coverage and integrate them with national schedules preventing a critical gap in early life protection.
• Elderly Vaccination: The targeting of older people with live attenuated vaccines comprises one of the key growth opportunities. Concerning severe infections, this group has a greater risk which has necessitated the development of specific vaccines to heighten immune responses among aged adults.
• Travel and Military Vaccination: There is an emerging market segment for live attenuated vaccines custom-made for travelers/ military personnel. For example these groups encounter unique pathogens hence targeted vaccination is inevitable for their well-being.
• Pandemic Preparedness: The priority of developing live attenuated vaccines for pandemic preparedness has been increasing lately. This category of vaccine is critically required as it aids in stockpiling and emergency use during health crisis thus partakers contribute to overall global health security efforts.
• Cancer Vaccines: The development of living attenuated vaccines for cancer treatment is an innovative growth opportunity. These vaccines are designed to prompt the immune system to recognize and eliminate cancer cells, offering a new way of treating cancer.

Innovation and expansion are being driven by these strategic growth opportunities in the live attenuated vaccine market. By targeting key applications, the market can meet crucial health requirements and support worldwide vaccination programs.

Live Attenuated Vaccine Market Driver and Challenges

Various drivers and challenges influence the live attenuated vaccine market among them being technological, economic as well as regulatory factors that shape the development and distribution of these vaccines.

The factors responsible for driving the live attenuated vaccine market include:

1. Technological Advancements: Innovations in vaccine technology such as mRNA and vector-based approaches drives the development of more effective and safer live attenuated vaccines. These advancements are broadening the market and increasing vaccine uptake.

2. Increasing Public Health Awareness: One major driver is rising awareness about the significance of immunization for prevention of communicable diseases. Public health campaigns disseminate information about the benefits associated with live attenuated vaccines thereby leading to increased vaccination rates.

3. Government Support: Strong government support including financing vaccine research and developing infrastructure has facilitated the growth of this market. In addition, governments have played a big role in ensuring regulatory approval as well as distributing vaccines.

4. Global Disease Burden: Demand for effective vaccines is driven by an increasing burden of infectious diseases globally. With their ability to confer strong immunity, live attenuated vaccines are considered indispensable for reducing disease incidence and mortality rate.

5. Pandemic Response: Pandemics require prompt and effective response, which is a significant push factor. In pandemic preparedness plans, live attenuated vaccines are given priority because they can be developed quickly and cover broad ranges.

Challenges in the live attenuated vaccine market are:

1. Regulatory Complexity: This challenge of vaccine developers is made harder by the intricate nature of regulatory environments in various parts of the world. The market entry could be delayed due to the need to comply with different regulations leading to high development costs.

2. Vaccine Hesitancy: Vaccine hesitancy still exists despite overwhelming evidence on their efficacy. Disinformation and doubts about the safety of vaccines may lead to less people getting vaccinated hence hampering public health efforts.

3. Production and Distribution Bottlenecks: Consistent supply of live attenuated vaccines remains a problem especially in low resource settings. There is an issue with vaccine availability and accessibility that arises from production capacity limitations as well as distribution challenges that emerge.

Innovation and expansion are powerful drivers that shape the live attenuated vaccine market but there are also some challenges that need attention for proper adoption and access across broad audience. Overcoming these challenges is essential for the market to fulfill its potential in improving global health outcomes.

List of Live Attenuated Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies live attenuated vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the live attenuated vaccine companies profiled in this report include-

• GlaxoSmithKline
• Merck & Co
• Medimmune
• Sanofi
• Serum Institute India
• Emergent Biosolutions
• CSL

Live Attenuated Vaccine by Segment

The study includes a forecast for the global live attenuated vaccine by type, end use, and region.

Live Attenuated Vaccine Market by Type [Analysis by Value from 2018 to 2030]:

• Bacterial
• Viral

Live Attenuated Vaccine Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospital
• Clinic
• Diagnostic Center
• Research Institute
• Others

Live Attenuated Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Live Attenuated Vaccine Market

The live attenuated vaccine market is witnessing significant advancements due to increased R&D investments, technological innovations, and growing demand for effective immunization strategies. Meanwhile, countries such as the U.S., China, Germany, India and Japan are leading this progress worldwide in live attenuated vaccines for preventing infectious diseases.

• United States: In the United States, recent developments in influenza and COVID-19 have focused on improving live attenuated vaccines. mRNA technology is being utilized by many firms to strengthen vaccine efficiency. On the other hand, FDA has sanctioned new formulations which target boosting immune responses specifically among young children and old people. Also, there are joint efforts between biotechnology companies and government agencies to expedite vaccine availability.
• China's live attenuated vaccine market has rapidly expanded especially after the emergence of COVID-19 pandemic in China. The government has invested heavily into vaccine development and manufacturing with an aim of increasing both local and international distributions. Furthermore, Chinese firms are fronting new ways of administering vaccines such as inhalable vaccines which are globally recognized for their simplicity during administration.
• Germany: Emphasis on innovation in live attenuated vaccines in Germany, especially in cancer and infectious disease prevention. New vaccine candidates, based on live attenuated vectors targeting specific pathogens, are being developed by German biotech firms. The country is also a part of global initiatives to enhance delivery and accessibility of vaccines so that new vaccines are taken to those people who do not have them.
• India: India plays a vital role in the manufacture and distribution of live attenuated vaccines due to its large scale production capabilities. In addition, recent developments have seen government-backed measures to improve vaccine manufacturing infrastructure and reduce costs. Moreover, Indian companies are reaching out globally while providing vaccinations to different nations as well as participating in worldwide vaccination drives.
• Japan: Concentration is on the next generation of improved safety and more effective live attenuated vaccines in Japan. Japanese government's focus is targeted at researching on emerging diseases for finding their possible vaccine options as well as improving internal productivity capacities. Furthermore, Japan teams up with the rest of world for development of regional health challenges like influenza and dengue fever specific vaccines among others.

Features of the Global Live Attenuated Vaccine Market

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Live attenuated vaccine market size by type, end use, and region in terms of value ($B).

Regional Analysis: Live attenuated vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, end uses, and regions for the live attenuated vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the live attenuated vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the live attenuated vaccine market size?

Answer: The global live attenuated vaccine market is expected to reach an estimated $9.8 billion by 2030.

Q.2 What is the growth forecast for live attenuated vaccine market?

Answer: The global live attenuated vaccine market is expected to grow with a CAGR of 9.5% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the live attenuated vaccine market?

Answer: The major drivers for this market are cumulating need for more effective vaccines, expanding awareness of the benefits of vaccination, and supportive government initiatives to promote vaccination programs.

Q4. What are the major segments for live attenuated vaccine market?

Answer: The future of the live attenuated vaccine market looks promising with opportunities in the hospital, clinic, diagnostics center, and research institute markets.

Q5. Who are the key live attenuated vaccine market companies?

Answer: Some of the key live attenuated vaccine companies are as follows:

• GlaxoSmithKline
• Merck & Co
• Medimmune
• Sanofi
• Serum Institute India
• Emergent Biosolutions
• CSL

Q6. Which live attenuated vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that viral is expected to witness higher growth over the forecast period due to its significant usage for the effective prevention of viral infections.

Q7. In live attenuated vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to the existence of well developed healthcare infrastructure and presence of supported government vaccination campaigns among individuals in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the live attenuated vaccine market by type (bacterial and viral), end use (hospital, clinic, diagnostics center, research institute, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global Live Attenuated Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Live Attenuated Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Live Attenuated Vaccine Market by Type
  • 3.3.1: Bacterial
  • 3.3.2: Viral
• 3.4: Global Live Attenuated Vaccine Market by End Use
  • 3.4.1: Hospital
  • 3.4.2: Clinic
  • 3.4.3: Diagnostic Center
  • 3.4.4: Research Institute
  • 3.4.5: others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Live Attenuated Vaccine Market by Region
• 4.2: North American Live Attenuated Vaccine Market
  • 4.2.1: North American Live Attenuated Vaccine Market by Type: Bacterial and Viral 4.2.2: North American Live Attenuated Vaccine Market by End Use: Hospital, Clinic, Diagnostic Center, Research Institute, and Others
• 4.3: European Live Attenuated Vaccine Market
  • 4.3.1: European Live Attenuated Vaccine Market by Type: Bacterial and Viral
  • 4.3.2: European Live Attenuated Vaccine Market by End Use: Hospital, Clinic, Diagnostic Center, Research Institute, and Others
• 4.4: APAC Live Attenuated Vaccine Market
  • 4.4.1: APAC Live Attenuated Vaccine Market by Type: Bacterial and Viral
  • 4.4.2: APAC Live Attenuated Vaccine Market by End Use: Hospital, Clinic, Diagnostic Center, Research Institute, and Others
• 4.5: ROW Live Attenuated Vaccine Market
  • 4.5.1: ROW Live Attenuated Vaccine Market by Type: Bacterial and Viral
  • 4.5.2: ROW Live Attenuated Vaccine Market by End Use: Hospital, Clinic, Diagnostic Center, Research Institute, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Live Attenuated Vaccine Market by Type
  • 6.1.2: Growth Opportunities for the Global Live Attenuated Vaccine Market by End Use
  • 6.1.3: Growth Opportunities for the Global Live Attenuated Vaccine Market by Region
• 6.2: Emerging Trends in the Global Live Attenuated Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Live Attenuated Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Live Attenuated Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: GlaxoSmithKline
• 7.2: Merck & Co
  • 7.1.1: MedImmune
• 7.4: Sanofi
• 7.5: Serum Institute India
• 7.6: Emergent Biosolutions
• 7.7: CSL